Labcorp Holdings Inc.(LH)
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Latest News & Analysis
Labcorp Holdings (LH) Q2 2025 Earnings and Strategic Advances in Oncology Diagnostics
Labcorp surpasses Q2 2025 earnings estimates with strong revenue growth and oncology innovations, raising full-year guidance amid competitive diagnostic landscape.
Laboratory Corporation of America Holdings (LH) Q2 2025 Earnings Beat and Strategic Growth Analysis
Explore Labcorp's Q2 2025 earnings beat driven by specialty diagnostics growth, acquisitions, raised guidance, and financial health insights.
Labcorp (LH) Q2 2025 Earnings Beat and Strategic Growth Drive Upward Guidance
Labcorp surpasses Q2 earnings estimates with strong diagnostics and acquisitions, raising full-year guidance. Strategic expansions in specialty and genetic testing bolster growth.
Laboratory Corporation of America Holdings (LH) Market Update: Precision Oncology and Strategic Growth Drive Financial Momentum
Explore Labcorp's latest financial results, strategic initiatives in precision oncology, workforce development, and strong cash flow underpinning sustained growth and market leadership.
Laboratory Corporation of America Holdings: Strategic Growth in Specialty Diagnostics and Biopharma
Labcorp's strategic pivot to specialty diagnostics and biopharma services is driving revenue growth, margin expansion, and strong investor interest in 2025.
Laboratory Corporation of America Holdings (LH) Specialty Testing Drives Earnings Growth and Market Position
Labcorp's strategic focus on specialty testing in oncology and neurology fuels revenue growth and strengthens competitive positioning amid strong financial performance.
Laboratory Corporation of America Holdings (LH) Q2 2025: Precision Oncology Expansion and Alzheimer's Test Drive Growth
Labcorp's strategic focus on precision oncology and Alzheimer's blood test innovation underpins robust Q2 2025 growth, supported by strong financials and acquisitions.
Labcorp (LH): Strategic Growth in Precision Oncology & Workforce Development
Labcorp's strategic pivot into precision oncology and a unique workforce partnership signal a significant shift, even as macroeconomic headwinds persist.
Labcorp (LH) Intensifies Focus on Oncology and Diagnostics
Labcorp's strategic moves in oncology and diagnostics, coupled with strong Q1 2025 results, position the company for growth despite valuation challenges.
Labcorp (LH): Self-Testing, Alzheimer's & Oncology Expansion
Labcorp (LH) expands diagnostics with self-testing, Alzheimer's advancements, and BioReference Health's oncology assets, aiming to boost revenue and investor confidence.
Labcorp's Oncology Expansion: Analyzing the BioReference Acquisition
Labcorp's acquisition of BioReference Health's oncology assets: financial implications, market impact, and future growth prospects analyzed.
Labcorp's Oncology Expansion: Analyzing the BioReference Deal
Labcorp's strategic acquisition of BioReference Health's oncology assets aims to expand its presence in the oncology diagnostics market.
Labcorp (LH): Strategic Acquisitions, Liquid Biopsy, and the Future of Diagnostics
Labcorp (LH) is strategically expanding its oncology services through acquisitions like BioReference Health and innovative diagnostics like Plasma Complete. Financial health is solid.
Labcorp (LH): Liquid Biopsy, Acquisitions, and Growth Analysis
Analysis of Labcorp's (LH) strategic moves, liquid biopsy test, and competitive landscape. Financial insights and growth opportunities for investors.
Labcorp (LH) Strategic Outlook: Liquid Biopsy, Fortrea Spin-off, and 2025 Growth Analysis
Labcorp (LH) is strategically navigating healthcare innovation with liquid biopsy, Fortrea spin-off, and strong 2025 growth projections. This analysis explores the key developments and insights.
Labcorp (LH): Q4 2024 Earnings, Strategic Initiatives
Labcorp's Q4 2024 results beat expectations, driven by strategic initiatives and growth in key markets. Investors should monitor Invitae integration and reimbursement landscape.
Labcorp (LH): Q4 2024 Performance, Strategic Initiatives
Labcorp (LH) reported strong Q4 2024 results, exceeding expectations. Strategic moves and innovative tests position it for growth, though margin compression is a concern.
Labcorp (LH) Q4 2024 Earnings: Strategic Growth and Market Outlook
Labcorp's Q4 2024 earnings showcase strategic growth and a positive market outlook, driven by innovative diagnostics and strategic initiatives.
Labcorp (LH): Q4 Earnings, Liquid Biopsy, and Strategic Outlook
Labcorp's Q4 earnings beat expectations, driven by strategic initiatives and liquid biopsy advancements. Margin pressures persist, but growth prospects remain strong.
Labcorp Q4 2024 Earnings: Strategic Initiatives & Market Impact
Labcorp exceeded Q4 2024 earnings expectations with robust revenue growth amid margin compression and strategic initiatives driving future market impact.
LabCorp Announces Major Business Developments
LabCorp's Q4 2024 earnings beat forecasts, but margin concerns linger. Strategic initiatives and market dynamics shape its path forward. Read the latest analysis.
LabCorp Announces Major Business Developments | Latest Industry News
LabCorp (LH) navigates strategic initiatives, Q4 earnings beat, and market dynamics amid analyst optimism and margin concerns.
Labcorp Core Strengths and Strategic Acquisitions Fuel Growth
Explore Labcorp's strong Q4 2024 earnings, strategic acquisitions including Invitae, and innovative initiatives that fuel growth and address market challenges.